Cadence Capital Management LLC bought a new stake in shares of ChemoCentryx Inc (NASDAQ:CCXI) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 95,344 shares of the biopharmaceutical company’s stock, valued at approximately $1,205,000.

A number of other hedge funds also recently modified their holdings of the stock. Sei Investments Co. raised its position in ChemoCentryx by 203.5% during the 2nd quarter. Sei Investments Co. now owns 8,549 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 5,732 shares during the last quarter. Macquarie Group Ltd. bought a new position in ChemoCentryx during the 2nd quarter valued at approximately $130,000. grace capital bought a new position in ChemoCentryx during the 2nd quarter valued at approximately $132,000. Paloma Partners Management Co bought a new position in ChemoCentryx during the 2nd quarter valued at approximately $159,000. Finally, Jane Street Group LLC bought a new position in ChemoCentryx during the 1st quarter valued at approximately $196,000. Institutional investors own 53.18% of the company’s stock.

In other news, insider Plc Glaxosmithkline sold 7,343,492 shares of the stock in a transaction that occurred on Tuesday, October 16th. The stock was sold at an average price of $11.69, for a total value of $85,845,421.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Markus J. Cappel sold 30,237 shares of the stock in a transaction that occurred on Friday, October 26th. The stock was sold at an average price of $11.01, for a total value of $332,909.37. Following the completion of the transaction, the insider now directly owns 54,063 shares of the company’s stock, valued at approximately $595,233.63. The disclosure for this sale can be found here. Insiders sold a total of 7,380,940 shares of company stock valued at $86,264,863 in the last three months. Corporate insiders own 14.50% of the company’s stock.

CCXI has been the subject of a number of recent analyst reports. BidaskClub raised ChemoCentryx from a “hold” rating to a “buy” rating in a research report on Tuesday, September 25th. ValuEngine lowered ChemoCentryx from a “buy” rating to a “hold” rating in a research report on Friday, September 7th. Canaccord Genuity reaffirmed a “buy” rating and set a $18.00 price target on shares of ChemoCentryx in a research report on Friday, August 10th. JPMorgan Chase & Co. lowered ChemoCentryx from an “overweight” rating to a “neutral” rating and upped their price target for the company from $14.00 to $15.00 in a research report on Tuesday, August 14th. Finally, Zacks Investment Research lowered ChemoCentryx from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 16th. Five analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. ChemoCentryx presently has a consensus rating of “Buy” and an average price target of $16.58.

Shares of NASDAQ:CCXI opened at $10.05 on Monday. ChemoCentryx Inc has a 52-week low of $5.42 and a 52-week high of $15.08. The company has a market capitalization of $505.62 million, a PE ratio of 40.20 and a beta of 1.78. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.69 and a quick ratio of 2.69.

ChemoCentryx (NASDAQ:CCXI) last announced its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.03. ChemoCentryx had a return on equity of 27.99% and a net margin of 13.88%. The firm had revenue of $8.98 million during the quarter, compared to analyst estimates of $11.55 million. Equities research analysts forecast that ChemoCentryx Inc will post -0.86 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Cadence Capital Management LLC Buys Shares of 95,344 ChemoCentryx Inc (CCXI)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.watchlistnews.com/cadence-capital-management-llc-buys-shares-of-95344-chemocentryx-inc-ccxi/2602331.html.

ChemoCentryx Profile

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).

Further Reading: What is the Dow Jones Industrial Average (DJIA)?

Want to see what other hedge funds are holding CCXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChemoCentryx Inc (NASDAQ:CCXI).

Institutional Ownership by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.